FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2738541296> ?p ?o ?g. }

• W2738541296 endingPage "1510" @default.
• W2738541296 startingPage "1499" @default.
• W2738541296 abstract "Background Cabotegravir and rilpivirine are antiretroviral drugs in development as long-acting injectable formulations. The LATTE-2 study evaluated long-acting cabotegravir plus rilpivirine for maintenance of HIV-1 viral suppression through 96 weeks. Methods In this randomised, phase 2b, open-label study, treatment-naive adults infected with HIV-1 initially received oral cabotegravir 30 mg plus abacavir–lamivudine 600–300 mg once daily. The objective of this study was to select an intramuscular dosing regimen based on a comparison of the antiviral activity, tolerability, and safety of the two intramuscular dosing regimens relative to oral cabotegravir plus abacavir–lamivudine. After a 20-week induction period on oral cabotegravir plus abacavir–lamivudine, patients with viral suppression (plasma HIV-1 RNA <50 copies per mL) were randomly assigned (2:2:1) to intramuscular long-acting cabotegravir plus rilpivirine at 4-week intervals (long-acting cabotegravir 400 mg plus rilpivirine 600 mg; two 2 mL injections) or 8-week intervals (long-acting cabotegravir 600 mg plus rilpivirine 900 mg; two 3 mL injections) or continued oral cabotegravir plus abacavir–lamivudine. Randomisation was computer-generated with stratification by HIV-1 RNA (<50 copies per mL, yes or no) during the first 12 weeks of the induction period. The primary endpoints were the proportion of patients with viral suppression at week 32 (as defined by the US Food and Drug Administration snapshot algorithm), protocol-defined virological failures, and safety events through 96 weeks. All randomly assigned patients who received at least one dose of study drug during the maintenance period were included in the primary efficacy and safety analyses. The primary analysis used a Bayesian approach to evaluate the hypothesis that the proportion with viral suppression for each long-acting regimen is not worse than the oral regimen proportion by more than 10% (denoted comparable) according to a prespecified decision rule (ie, posterior probability for comparability >90%). Difference in proportions and associated 95% CIs were supportive to the primary analysis. The trial is registered at ClinicalTrials.gov, number NCT02120352. Findings Among 309 enrolled patients, 286 were randomly assigned to the maintenance period (115 to each of the 4-week and 8-week groups and 56 to the oral treatment group). This study is currently ongoing. At 32 weeks following randomisation, both long-acting regimens met primary criteria for comparability in viral suppression relative to the oral comparator group. Viral suppression was maintained at 32 weeks in 51 (91%) of 56 patients in the oral treatment group, 108 (94%) of 115 patients in the 4-week group (difference 2·8% [95% CI −5·8 to 11·5] vs oral treatment), and 109 (95%) of 115 patients in the 8-week group (difference 3·7% [−4·8 to 12·2] vs oral treatment). At week 96, viral suppression was maintained in 47 (84%) of 56 patients receiving oral treatment, 100 (87%) of 115 patients in the 4-week group, and 108 (94%) of 115 patients in the 8-week group. Three patients (1%) experienced protocol-defined virological failure (two in the 8-week group; one in the oral treatment group). Injection-site reactions were mild (3648 [84%] of 4360 injections) or moderate (673 [15%] of 4360 injections) in intensity and rarely resulted in discontinuation (two [<1%] of 230 patients); injection-site pain was reported most frequently. Serious adverse events during maintenance were reported in 22 (10%) of 230 patients in the intramuscular groups (4-week and 8-week groups) and seven (13%) of 56 patients in the oral treatment group; none were drug related. Interpretation The two-drug combination of all-injectable, long-acting cabotegravir plus rilpivirine every 4 weeks or every 8 weeks was as effective as daily three-drug oral therapy at maintaining HIV-1 viral suppression through 96 weeks and was well accepted and tolerated. Funding ViiV Healthcare and Janssen R&D. Cabotegravir and rilpivirine are antiretroviral drugs in development as long-acting injectable formulations. The LATTE-2 study evaluated long-acting cabotegravir plus rilpivirine for maintenance of HIV-1 viral suppression through 96 weeks. In this randomised, phase 2b, open-label study, treatment-naive adults infected with HIV-1 initially received oral cabotegravir 30 mg plus abacavir–lamivudine 600–300 mg once daily. The objective of this study was to select an intramuscular dosing regimen based on a comparison of the antiviral activity, tolerability, and safety of the two intramuscular dosing regimens relative to oral cabotegravir plus abacavir–lamivudine. After a 20-week induction period on oral cabotegravir plus abacavir–lamivudine, patients with viral suppression (plasma HIV-1 RNA <50 copies per mL) were randomly assigned (2:2:1) to intramuscular long-acting cabotegravir plus rilpivirine at 4-week intervals (long-acting cabotegravir 400 mg plus rilpivirine 600 mg; two 2 mL injections) or 8-week intervals (long-acting cabotegravir 600 mg plus rilpivirine 900 mg; two 3 mL injections) or continued oral cabotegravir plus abacavir–lamivudine. Randomisation was computer-generated with stratification by HIV-1 RNA (<50 copies per mL, yes or no) during the first 12 weeks of the induction period. The primary endpoints were the proportion of patients with viral suppression at week 32 (as defined by the US Food and Drug Administration snapshot algorithm), protocol-defined virological failures, and safety events through 96 weeks. All randomly assigned patients who received at least one dose of study drug during the maintenance period were included in the primary efficacy and safety analyses. The primary analysis used a Bayesian approach to evaluate the hypothesis that the proportion with viral suppression for each long-acting regimen is not worse than the oral regimen proportion by more than 10% (denoted comparable) according to a prespecified decision rule (ie, posterior probability for comparability >90%). Difference in proportions and associated 95% CIs were supportive to the primary analysis. The trial is registered at ClinicalTrials.gov, number NCT02120352. Among 309 enrolled patients, 286 were randomly assigned to the maintenance period (115 to each of the 4-week and 8-week groups and 56 to the oral treatment group). This study is currently ongoing. At 32 weeks following randomisation, both long-acting regimens met primary criteria for comparability in viral suppression relative to the oral comparator group. Viral suppression was maintained at 32 weeks in 51 (91%) of 56 patients in the oral treatment group, 108 (94%) of 115 patients in the 4-week group (difference 2·8% [95% CI −5·8 to 11·5] vs oral treatment), and 109 (95%) of 115 patients in the 8-week group (difference 3·7% [−4·8 to 12·2] vs oral treatment). At week 96, viral suppression was maintained in 47 (84%) of 56 patients receiving oral treatment, 100 (87%) of 115 patients in the 4-week group, and 108 (94%) of 115 patients in the 8-week group. Three patients (1%) experienced protocol-defined virological failure (two in the 8-week group; one in the oral treatment group). Injection-site reactions were mild (3648 [84%] of 4360 injections) or moderate (673 [15%] of 4360 injections) in intensity and rarely resulted in discontinuation (two [<1%] of 230 patients); injection-site pain was reported most frequently. Serious adverse events during maintenance were reported in 22 (10%) of 230 patients in the intramuscular groups (4-week and 8-week groups) and seven (13%) of 56 patients in the oral treatment group; none were drug related. The two-drug combination of all-injectable, long-acting cabotegravir plus rilpivirine every 4 weeks or every 8 weeks was as effective as daily three-drug oral therapy at maintaining HIV-1 viral suppression through 96 weeks and was well accepted and tolerated." @default.
• W2738541296 created "2017-07-31" @default.
• W2738541296 creator A5002944057 @default.
• W2738541296 creator A5007250313 @default.
• W2738541296 creator A5009272615 @default.
• W2738541296 creator A5010243286 @default.
• W2738541296 creator A5010795386 @default.
• W2738541296 creator A5011202454 @default.
• W2738541296 creator A5012384912 @default.
• W2738541296 creator A5014137251 @default.
• W2738541296 creator A5017860407 @default.
• W2738541296 creator A5024560316 @default.
• W2738541296 creator A5028130303 @default.
• W2738541296 creator A5032988057 @default.
• W2738541296 creator A5034571044 @default.
• W2738541296 creator A5036087352 @default.
• W2738541296 creator A5043793286 @default.
• W2738541296 creator A5044001938 @default.
• W2738541296 creator A5047561314 @default.
• W2738541296 creator A5048197121 @default.
• W2738541296 creator A5048320845 @default.
• W2738541296 creator A5061678587 @default.
• W2738541296 creator A5061966779 @default.
• W2738541296 creator A5064601780 @default.
• W2738541296 creator A5081802444 @default.
• W2738541296 creator A5088973852 @default.
• W2738541296 date "2017-09-01" @default.
• W2738541296 modified "2023-10-14" @default.
• W2738541296 title "Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial" @default.
• W2738541296 cites W1674196795 @default.
• W2738541296 cites W1982222817 @default.
• W2738541296 cites W1995101760 @default.
• W2738541296 cites W2024823439 @default.
• W2738541296 cites W2030599394 @default.
• W2738541296 cites W2075144974 @default.
• W2738541296 cites W2081607626 @default.
• W2738541296 cites W2085167526 @default.
• W2738541296 cites W2136683144 @default.
• W2738541296 cites W2151102304 @default.
• W2738541296 cites W2320058171 @default.
• W2738541296 cites W2322601374 @default.
• W2738541296 cites W2394662221 @default.
• W2738541296 cites W2395339327 @default.
• W2738541296 cites W590937065 @default.
• W2738541296 doi "https://doi.org/10.1016/s0140-6736(17)31917-7" @default.
• W2738541296 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28750935" @default.
• W2738541296 hasPublicationYear "2017" @default.
• W2738541296 type Work @default.
• W2738541296 sameAs 2738541296 @default.
• W2738541296 citedByCount "372" @default.
• W2738541296 countsByYear W27385412962017 @default.
• W2738541296 countsByYear W27385412962018 @default.
• W2738541296 countsByYear W27385412962019 @default.
• W2738541296 countsByYear W27385412962020 @default.
• W2738541296 countsByYear W27385412962021 @default.
• W2738541296 countsByYear W27385412962022 @default.
• W2738541296 countsByYear W27385412962023 @default.
• W2738541296 crossrefType "journal-article" @default.
• W2738541296 hasAuthorship W2738541296A5002944057 @default.
• W2738541296 hasAuthorship W2738541296A5007250313 @default.
• W2738541296 hasAuthorship W2738541296A5009272615 @default.
• W2738541296 hasAuthorship W2738541296A5010243286 @default.
• W2738541296 hasAuthorship W2738541296A5010795386 @default.
• W2738541296 hasAuthorship W2738541296A5011202454 @default.
• W2738541296 hasAuthorship W2738541296A5012384912 @default.
• W2738541296 hasAuthorship W2738541296A5014137251 @default.
• W2738541296 hasAuthorship W2738541296A5017860407 @default.
• W2738541296 hasAuthorship W2738541296A5024560316 @default.
• W2738541296 hasAuthorship W2738541296A5028130303 @default.
• W2738541296 hasAuthorship W2738541296A5032988057 @default.
• W2738541296 hasAuthorship W2738541296A5034571044 @default.
• W2738541296 hasAuthorship W2738541296A5036087352 @default.
• W2738541296 hasAuthorship W2738541296A5043793286 @default.
• W2738541296 hasAuthorship W2738541296A5044001938 @default.
• W2738541296 hasAuthorship W2738541296A5047561314 @default.
• W2738541296 hasAuthorship W2738541296A5048197121 @default.
• W2738541296 hasAuthorship W2738541296A5048320845 @default.
• W2738541296 hasAuthorship W2738541296A5061678587 @default.
• W2738541296 hasAuthorship W2738541296A5061966779 @default.
• W2738541296 hasAuthorship W2738541296A5064601780 @default.
• W2738541296 hasAuthorship W2738541296A5081802444 @default.
• W2738541296 hasAuthorship W2738541296A5088973852 @default.
• W2738541296 hasBestOaLocation W27385412962 @default.
• W2738541296 hasConcept C126322002 @default.
• W2738541296 hasConcept C141071460 @default.
• W2738541296 hasConcept C142462285 @default.
• W2738541296 hasConcept C159047783 @default.
• W2738541296 hasConcept C168563851 @default.
• W2738541296 hasConcept C2778723075 @default.
• W2738541296 hasConcept C2993143319 @default.
• W2738541296 hasConcept C3013748606 @default.
• W2738541296 hasConcept C3019800554 @default.
• W2738541296 hasConcept C71924100 @default.
• W2738541296 hasConceptScore W2738541296C126322002 @default.
• W2738541296 hasConceptScore W2738541296C141071460 @default.
• W2738541296 hasConceptScore W2738541296C142462285 @default.
• W2738541296 hasConceptScore W2738541296C159047783 @default.
• W2738541296 hasConceptScore W2738541296C168563851 @default.

• next